
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination... BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.075 | 2.17391304348 | 3.45 | 3.73 | 3.3206 | 40261 | 3.55603136 | CS |
4 | -0.255 | -6.74603174603 | 3.78 | 5.4 | 3 | 123364 | 4.34178471 | CS |
12 | -5.925 | -62.6984126984 | 9.45 | 9.75 | 3 | 762342 | 6.08726755 | CS |
26 | -5.925 | -62.6984126984 | 9.45 | 21.3 | 3 | 1892491 | 11.26775617 | CS |
52 | -41.025 | -92.0875420875 | 44.55 | 45.6 | 3 | 1757059 | 10.9174011 | CS |
156 | -122.925 | -97.2123368921 | 126.45 | 181.35 | 3 | 762617 | 33.52213562 | CS |
260 | -60.075 | -94.4575471698 | 63.6 | 187.05 | 3 | 1126132 | 65.69471636 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.